FEMARA
Total Payments
$348,380
Transactions
117
Doctors
80
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $8,672 | 16 | 15 |
| 2022 | $24,649 | 87 | 63 |
| 2021 | $6,355 | 3 | 2 |
| 2020 | $37,912 | 3 | 0 |
| 2019 | $47,742 | 2 | 0 |
| 2018 | $58,975 | 1 | 0 |
| 2017 | $164,074 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $346,615 | 14 | 99.5% |
| Food and Beverage | $1,764 | 103 | 0.5% |
Payments by Type
Research
$346,615
14 transactions
General
$1,764
103 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ENDOCRINE THERAPY IN COMBINATION WITH ANTI VEGF THERAPY A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE THERAPY PLUS BEVACIZUMAB NSC 704865 IND 7921 FOR WOMEN WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER | Novartis Pharmaceuticals Corporation | $180,435 | 0 |
| ENDOCRINE THERAPY IN COMBINATION WITH ANTI VEGF THERAPY A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE THERAPY PLUS BEVACIZUMAB NSC 704865 IND 7921 FOR WOMEN WITH HORMONE RECEPTOR POSITIVE ADVANCED BRE | Novartis Pharmaceuticals Corporation | $108,823 | 0 |
| RE SURGICAL TRIAL OF LETROZOLE ON POST MENOPAUSAL WOMEN WITH OPERABLE HORMONE SENSITIVE BREAST CANCER | Novartis Pharmaceuticals Corporation | $30,000 | 0 |
| PHASE I AND OR II TRIAL OF LETROZOLE FEMARA AND SORAFENIB NEXAVAR IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $16,850 | 0 |
| Endocrine Therapy in Combination With anti VEGF Therapy A randomized double blind placebo controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab NSC 704865 IND 7921 for Women With Hormone Receptor Positive Advanced Breast Cancer | Novartis Pharmaceuticals Corporation | $8,425 | 0 |
| A RANDOMIZED CONTROLLED TRIAL OF THE USE OF AROMATASE INHIBITORS ALONE AND IN COMBINATION WITH GROWTH HORMONE IN ADOLESCENT BOYS WITH IDIOPATHIC SHORT STATURE | Novartis Pharmaceuticals Corporation | $2,083 | 0 |
Top Doctors Receiving Payments for FEMARA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | Fleming Island, FL | $17.25 | 1 |
| , M.D | Hematology | Fleming Island, FL | $17.25 | 1 |
| , DO | Hematology | Fleming Island, FL | $17.25 | 1 |
| , MD | Medical Oncology | Lake City, FL | $16.02 | 1 |
| , M.D | Medical Oncology | Lake City, FL | $16.02 | 1 |
| , ARNP | Adult Health | Lake City, FL | $16.02 | 1 |
| , FNP | Nurse Practitioner | Dyer, IN | $15.65 | 1 |
| , MD | Hematology & Oncology | Jacksonville, FL | $15.39 | 1 |
| , MD | Hematology & Oncology | Jacksonville, FL | $15.39 | 1 |
| , MD | Hematology & Oncology | Jacksonville, FL | $15.39 | 1 |
| , ARNP | Adult Health | Jacksonville, FL | $15.39 | 1 |
| , PA-C | Medical | Jacksonville, FL | $15.39 | 1 |
| , M.D | Internal Medicine | Jacksonville, FL | $15.39 | 1 |
| , MD | Hematology & Oncology | Jacksonville, FL | $15.39 | 1 |
| , PA-C | Physician Assistant | Savannah, GA | $14.46 | 1 |
| , AGACNP-BC | Acute Care | Statesboro, GA | $14.46 | 1 |
| , APRN | Adult Health | Independence, KS | $14.06 | 1 |
| , NP | Nurse Practitioner | Savannah, GA | $13.77 | 1 |
| , MD | Internal Medicine | Pikeville, KY | $13.72 | 1 |
| , APRN | Nurse Practitioner | Pikeville, KY | $13.72 | 1 |
| , M.D | Hematology & Oncology | Mountain Lakes, NJ | $10.34 | 1 |
| , M.D | Hematology & Oncology | San Bernardino, CA | $8.87 | 1 |
| , M.D | Hematology & Oncology | San Bernardino, CA | $8.87 | 1 |
| , MD | Hematology & Oncology | Waycross, GA | $8.37 | 1 |
| , M.D | Medical Oncology | Deland, FL | $7.46 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $348,380
- Total Doctors 80
- Transactions 117
About FEMARA
FEMARA is a drug associated with $348,380 in payments to 80 healthcare providers, recorded across 117 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2023. In 2023, $8,672 was paid across 16 transactions to 15 doctors.
The most common payment nature for FEMARA is "Unspecified" ($346,615, 99.5% of total).
FEMARA is associated with 6 research studies, including "ENDOCRINE THERAPY IN COMBINATION WITH ANTI VEGF THERAPY A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE THERAPY PLUS BEVACIZUMAB NSC 704865 IND 7921 FOR WOMEN WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER" ($180,435).